CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - New Zealand

  • ID: 4538960
  • Report
  • Region: New Zealand
  • 117 pages
  • GlobalData
1 of 3
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - New Zealand

Summary

New Zealand is a mature healthcare market with a strong regulatory environment. The largest and fastest growing segment of biologics is monoclonal antibodies, which accounts for around $110m per annum. It spends approximately 11% of its GDP on healthcare. In 2015, the pharmaceutical sales declined to around $688m from around $796m in 2014. This again rose to around $746 in 2016. The market is forecast to grow to and cross $1 billion in 2022; at a CAGR of around 6%. In 2010, the medical device market in New Zealand was worth about $1.17 billion, which increased to around $1.4 billion in 2017. It is expected to grow at a CAGR of about 3.4% from around $1.5 billion in 2018 to $1.8 billion in 2022.

The main segments were ophthalmic devices, wound care management, healthcare IT, orthopedic devices and in vitro diagnostics. The increasing elderly population and high investment in R&D expenditure are expected to drive the growth of pharmaceutical market. However, high penetration of generics in the market and the policies of PHARMAC, pose as a barrier for the multinational pharmaceutical manufacturers

The government of New Zealand encourages innovation and supports biomedical and drug development research with continuous investment in science, research and technology as a mechanism to increase the knowledge economy.

The report "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - New Zealand", provides information on the healthcare, regulatory, and reimbursement landscape in New Zealand, and includes:
  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market (Douglas, Mylan, GSK, Merck and NZP) and profiles and SWOT analyses of the major players in the medical device market (Medtronic, GE Healthcare, DePuy Synthes, Essilor and Fisher & Paykel Healthcare)
  • Detailed analysis about recent completed deals in the pharmaceutical and medical device market of New Zealand
  • Porter’s five forces analysis for pharmaceutical and medical devices market of New Zealand
  • An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
  • Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the New Zealand healthcare market
Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in New Zealand, and includes:
  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market (Douglas, Mylan, GSK, Merck and NZP) and profiles and SWOT analyses of the major players in the medical device market (Medtronic, GE Healthcare, DePuy Synthes, Essilor and Fisher & Paykel Healthcare)
  • Detailed analysis about recent completed deals in the pharmaceutical and medical device market of New Zealand
  • Porter’s five forces analysis for pharmaceutical and medical devices market of New Zealand
  • An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
  • Information regarding recent healthcare policies along with healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the New Zealand healthcare market.
Reasons to buy

This report will enhance your decision-making capability by allowing you to:
  • Develop business strategies by understanding the trends shaping and driving the New Zealand healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
  • Identify, understand, and capitalize on the opportunities and challenges in the New Zealand healthcare market.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
  • Executive Summary
  • Overview of Pharmaceutical Market
  • Overview of Medical Device Market
  • Deals Analysis
  • Porter’s Five Forces Model
  • Market Access
  • Country Healthcare Landscape
  • Opportunities and Challenges
  • Appendix
List of Tables
Table 1: Pharmaceutical Market, New Zealand, Self medication product groups sales ($m), 2016
Table 2: Pharmaceutical Market, New Zealand, Major therapeutic groups based on sales ($m), 2014
Table 3: Medical Device Market, New Zealand, Revenue by Segment ($m) and market share (%), 2017
Table 4: Ophthalmic Devices Market, New Zealand, Revenue ($m) and Market Share (%) of Major Companies, 2015
Table 5: Wound Care Management Market, New Zealand, Revenue ($m) and Market Share (%) of Major Companies, 2017
Table 6: Healthcare IT Devices Market, New Zealand, Revenue ($m) and Market Share (%) of Major Companies, 2015
Table 7: Orthopedic Devices Market, New Zealand, Revenue ($m) and Market Share (%) of Major Companies, 2016
Table 8: IVD Market, New Zealand, Revenue ($m) and Market Share (%) of Major Companies, 2017
Table 9: NMA Fees, New Zealand, 2017
Table 10: Patent Fees, New Zealand, 2017
Table 11: Trademark Fees, New Zealand, 2017
Table 12: Clinical Trial Application Fees, New Zealand, 2015
Table 13: Pharmacy Regulations, New Zealand, 2011
Table 14: Labeling and Packaging Regulations, New Zealand, 2018
Table 15: Trade Fairs, New Zealand 101

List of Figures
Figure 1: Pharmaceutical Market, New Zealand, Revenue ($m), 2010-2017
Figure 2: Medical Device Market, New Zealand, Revenue ($bn), 2010-2017
Figure 3: Country Profile, New Zealand, 2018
Figure 4: Pharmaceutical Market, New Zealand, Revenue ($m), 2010-2017
Figure 5: Pharmaceutical Market, New Zealand, Revenue Forecast ($m), 2018-2022
Figure 6: Pharmaceutical Exports ($m), New Zealand, 2010-2017
Figure 7: Top Export Partners, New Zealand, 2016
Figure 8: Pharmaceutical Imports ($m), New Zealand, 2010-2017
Figure 9: Top Import Partners, New Zealand, 2016
Figure 10: Distribution Channels, New Zealand, 2016
Figure 11: Pharmaceutical Market, New Zealand, Major therapeutic groups based on sales ($m), 2014
Figure 12: Pharmaceutical Market, New Zealand, Major Players
Figure 13: Medical Device Market, New Zealand, Revenue ($bn), 2010-2017
Figure 14: Medical Device Market, New Zealand, Revenue Forecast ($bn), 2018-2022
Figure 15: Medical Device Market, New Zealand, Revenue by Segment ($m), 2017
Figure 16: Ophthalmic Devices Market, New Zealand, Revenue ($m), 2010-2017
Figure 17: Ophthalmic Devices Market, New Zealand, Market Share of Major Players (%), 2015
Figure 18: Wound Care Management Market, New Zealand, Revenue ($m), 2010-2017
Figure 19: Wound Care Management Market, New Zealand, Market Share of Major Players (%), 2017
Figure 20: Healthcare IT Devices Market, New Zealand, Revenue ($m), 2010-2017
Figure 21: Healthcare IT Devices Market, New Zealand, Market Share of Major Players (%), 2015
Figure 22: Orthopedic Devices Market, New Zealand, Revenue ($m), 2010-2017
Figure 23: Orthopedic Devices Market, New Zealand, Market Share of Major Players (%), 2016
Figure 24: IVD Market, New Zealand, Revenue ($m), 2010-2017
Figure 25: IVD Market, New Zealand, Market Share of Major Companies (%), 2017
Figure 26: Diagnostic Market, New Zealand, Revenue ($bn), 2010-2017
Figure 27: Diagnostic Market, New Zealand, Revenue ($bn), 2018-2022
Figure 28: Medical Device Market, New Zealand, Revenue ($bn) of Major Companies, 2016
Figure 29: Deal Value and Deal Count, Pharmaceutical Market, New Zealand, 2017-2018
Figure 30: Deal Value and Deal Count Quarterly, Pharmaceutical Market, New Zealand, 2017-2018
Figure 31:Deal Value and Deal Count Sub-Types, Pharmaceutical Market, New Zealand, 2017-2018
Figure 32: Top 5 therapy area by deal value, Pharmaceutical Market, New Zealand, 2017-2018
Figure 33: Top 5 therapy area by deal number, Pharmaceutical Market, New Zealand, 2017-2018
Figure 34: M&A deals by therapy area, Pharmaceutical Market, New Zealand, 2017-2018 (By value and by number)
Figure 35: Venture Financing deals by therapy area, Pharmaceutical Market, New Zealand, 2017-2018 (By value and by number)
Figure 36: Private Equity deals by therapy area, Pharmaceutical Market New Zealand, 2017-2018 (By value and by number)
Figure 37: Overview of Healthcare System, New Zealand, 2015
Figure 38: Drug Funding/Reimbursement Approval Process , New Zealand, 2013
Figure 39: Out-of-Pocket Expenditure (% of total expenditure on health), New Zealand, 2010-2017
Figure 40: Change in Health CPI(%), New Zealand , 2009-2016
Figure 41: Process of Drug Funding, New Zealand
Figure 42: MEDSAFE, Organizational structure, New Zealand, 2015
Figure 43: Market Authorization Procedure, New Zealand, 2015
Figure 44: WAND Process, New Zealand
Figure 45: Licensing Process for Pharmaceutical Manufacturing, New Zealand
Figure 46: Patent Approval Process, New Zealand, 2017
Figure 47: Trademark Approval Process, New Zealand, 2017
Figure 48: Clinical Trial Regulation Process, New Zealand, 2015
Figure 49: Pharmaceutical Advertisement Approval Process, New Zealand, 2011
Figure 50: Hospitals (Number), New Zealand, 2010-2017
Figure 51: Public - Private Hospitals (Number), New Zealand, 2010-2017
Figure 52: Diagnostic Equipment (Number), New Zealand, 2010-2017
Figure 53: Hospital Beds (per 1,000 population), New Zealand, 2010 - 2017
Figure 54: Life Expectancy (years), New Zealand, 2010-2017
Figure 55: Immunization Rate (%), New Zealand, 2010-2017
Figure 56: Major Causes of Mortality, No. of deaths (‘000), New Zealand, 2012
Figure 57: Major Causes of Male Mortality, No. of deaths (‘000), New Zealand, 2015
Figure 58: Major Causes of Female Mortality, No. of deaths (‘000), New Zealand, 2015
Figure 59: Disability-Adjusted Life Years by Major Disease (‘000), New Zealand, 2015
Figure 60: Physicians (per 1,000 population), New Zealand, 2010-2017
Figure 61: Dentists, (per 1,000 population), New Zealand, 2010-2017
Figure 62: Nurses (per 1,000 population), New Zealand, 2010-2017
Figure 63: Pharmacists, (per 1,000 population), New Zealand, 2010-2017
Figure 64: PM2.5 (µg per m3), New Zealand, 2010-2017
Figure 65: CO2 Emissions (k tons), New Zealand, 2010-2017
Figure 66: Healthcare Expenditure (% of GDP ), New Zealand, 2010-2017
Figure 67: Public-Private Share (%), New Zealand, 2010-2017
Figure 68: Major Components of Healthcare Spending (%), New Zealand, 2011
Figure 69: Spending in R&D by sector ($m) , New Zealand, 2008-2016
Figure 70: Opportunities and Challenges
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll